ClinicalTrials.gg
RecruitingNCT06970236IHOPEUpdated May 28, 2025

Resistance Exercise in Patients With Ocular Melanoma

An interventional study of Exercise in Ocular Melanoma, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by University of Valencia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Uveal Melanoma with a site in Spain — 4 open to participants now, 11 under way, 4 of them phase 3. Uveal Melanoma · Spain.

Planned enrollment
16th of 22
40 · median 94
Started
2025
with 1 other
No phase
Only one
of the 22
Primary completion
2026-12
later than 3 of 10 live
Registered
21st of 22
by date

Among the 22 studies in Uveal Melanoma with a site in Spain, this one is the 16th largest by planned enrollment, is one of 2 that started in 2025, is the only one with no phase, reaches primary completion later than 3 of the 10 other live ones, and was the 21st registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

4 of the 22 studies in Uveal Melanoma with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Uveal Melanoma with a site in Spain, or all of them as a file.
02

Study summary

Choroidal melanoma (CM) is one of the most common intraocular cancers worldwide. During treatment with episcleral brachytherapy, patients require a week of hospitalization in isolation. The primary aim of this study will be to investigate the effects of resistance training during hospitalization on health-related blood biomarkers in CM patients. Our secondary aim will be to assess changes in physical function tests, quality of life and anxiety and depression. Candidates for this study will be patients undergoing CM treatment at the "Hospital Universitari i Politècnic La Fe" of Valencia.

Read the detailed description

Candidates of the present study will be adults with CM diagnose and treated with plaque brachytherapy undergoing in "Hospital Universitari i Politècnic La Fe" (Valencia). All the participants will be informed about the objectives and content of the investigation and written informed consent will be obtained. Participants will be excluded if they (1) present a health status that forbids high intensity resistance training, (2) have any unsteady cardiac illness, (3) have serious metabolic disorder or if (4) they have any important orthopaedic disorder impeding exercise. The study will conform to the Declaration of Helsinki and will be approved by the Ethical Committee of "Hospital Universitari i Politècnic de La Fe".

A randomized controlled trial with two parallel groups is planned: a control group following the hospital's standard protocol (usual care) and an intervention group in which patients will complete a daily resistance training session during hospitalization. During the 5-7 days of treatment, where participants are going to be isolated in a room without human contact, are going to perform a daily session of exercise during about 30 minutes. The exercises will be supervised by a trained physician. To carry out the training session, elastic resistance bands will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.

To observe the effects of the intervention, various blood tests, functional, quality-of-life and anxiety and depression assessments will be conducted before and after the program, as well as one-month post-hospital discharge.

03

Conditions studied

  • Ocular Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with Choroidal Melanoma diagnose and treated with plaque brachytherapy undergoing in "Hospital Universitari i Politècnic La Fe" (Valencia).

Exclusion criteria

Exclusion Criteria:

  • Present a health status that forbids high intensity resistance training.
  • Have any unsteady cardiac illness.
  • Have serious metabolic disorder.
  • Have any important orthopaedic disorder impeding exercise.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Exercise Intervention Group

    Participants on this group will follow the exercise intervention mentioned in the protocol.

    Other: Exercise

  • No intervention
    Control Group

    Patients in the control group will follow the hospital's conventional protocol during the hospitalization days, which consists in isolated bed rest.

Interventions

  • OtherExercise

    Daily session during hospitalization. To carry out the training session, elastic bands (TheraBand CLX Consecutive Loops; TheraBand, Akron, OH) with resistance graded from very low to very high (i.e, yellow, red, green, blue, black, silver and gold) will be used. On each day, each exercise will start with 3 sets of two repetitions as a warm-up and to calculate the appropriate intensity. The intensity will be that at which the patient reports a perceived exertion of 5-6 of 10 at the Borg CR10 scale after two repetitions. For each exercise, one set will be completed until task failure is achieved.If in any of the exercises the patient perceives this intensity only with the weight of his own limb or body weight, the exercise will be performed without elastic bands.

06

What researchers measure

Primary outcomes

  1. Blood biomarkers: glucose

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  2. Blood biomarkers: urea

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  3. Blood biomarkers: creatinine

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  4. Blood biomarkers: glomerular filtration

    Metabolic and lipidic response marker measured in milliliters/minutes/1,73 (ml/min/1,73).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  5. Blood biomarkers: total bilirubin

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  6. Blood biomarkers: aspartate aminotransferase

    Metabolic and lipidic response marker measured in units/liter (U/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  7. Blood biomarkers: alanine aminotransferase

    Metabolic and lipidic response marker measured in units/liter (U/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  8. Blood biomarkers: alkaline phosphatase

    Metabolic and lipidic response marker measured in units/liter (U/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  9. Blood biomarkers: lactate dehydrogenase

    Metabolic and lipidic response marker measured in units/liter (U/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  10. Blood biomarkers: creatine kinase

    Metabolic and lipidic response marker measured in units/liter (U/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  11. Blood biomarkers: total proteins

    Metabolic and lipidic response marker measured in grams/deciliter (g/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  12. Blood biomarkers: albumin

    Metabolic and lipidic response marker measured in grams/deciliter (g/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  13. Blood biomarkers: C-reactive protein

    Inflammatory response marker measured in milligrams/liter (mg/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  14. Blood biomarkers: interleukin 6

    Inflammatory response marker measured in picograms/milliliter (pg/ml).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  15. Blood biomarkers: calcium

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  16. Blood biomarkers: albumine-corrected calcium

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  17. Blood biomarkers: chloride

    Metabolic and lipidic response marker measured in milliequivalents/liter (mEq/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  18. Blood biomarkers: sodium

    Metabolic and lipidic response marker measured in milliequivalents/liter (mEq/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  19. Blood biomarkers: potassium

    Metabolic and lipidic response marker measured in milliequivalents/liter (mEq/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  20. Blood biomarkers: total cholesterol

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  21. Blood biomarkers: HDL cholesterol

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  22. Blood biomarkers: LDL cholesterol

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  23. Blood biomarkers: no HDL cholesterol

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  24. Blood biomarkers: triglycerides

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  25. Blood biomarkers: hematies

    Blood marker measured in x10\^6/microliter (x10\^6/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  26. Blood biomarkers: hemoglobin

    Blood marker measured in grams/deciliter (g/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  27. Blood biomarkers: hematocrit

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  28. Blood biomarkers: mean corpuscular volume

    Blood marker measured in femtoliters (fL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  29. Blood biomarkers: mean corpuscular hemoglobine

    Blood marker measured in picograms (pg).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  30. Blood biomarkers: mean corpuscular hemoglobin concentration

    Blood marker measured in grams/deciliter (g/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  31. Blood biomarkers: red cell distribution width - standard deviation

    Blood marker measured in femtoliters (fL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  32. Blood biomarkers: red cell distribution width - coefficient of variation

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  33. Blood biomarkers: erythroblasts

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  34. Blood biomarkers: leukocytes

    Blood marker measured in x10\^3/microliter (x10\^3/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  35. Blood biomarkers: neutrophils

    Blood marker measured in x10\^3/microliter (x10\^3/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  36. Blood biomarkers: lymphocytes

    Blood marker measured in x10\^3/microliter (x10\^3/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  37. Blood biomarkers: monocytes

    Blood marker measured in x10\^3/microliter (x10\^3/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  38. Blood biomarkers: eosinophils

    Blood marker measured in x10\^3/microliter (x10\^3/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  39. Blood biomarkers: basophils

    Blood marker measured in x10\^3/microliter (x10\^3/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  40. Blood biomarkers: neutrophils %

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  41. Blood biomarkers: lymphocytes %

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  42. Blood biomarkers: monocytes %

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  43. Blood biomarkers: eosinophils %

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  44. Blood biomarkers: basophils %

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  45. Blood biomarkers: immature granulocytes %

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  46. Blood biomarkers: platelets

    Blood marker measured in x10\^3/microliter (x10\^3/µL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  47. Blood biomarkers: mean platelet volume

    Blood marker measured in femtoliters (fL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  48. Blood biomarkers: platelet distribution width

    Blood marker measured in femtoliters (fL).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  49. Blood biomarkers: platelet large cell ratio

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  50. Blood biomarkers: prothrombin time

    Blood marker measured in seconds (sec).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  51. Blood biomarkers: prothrombin time ratio

    Blood marker.

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  52. Blood biomarkers: Quick index

    Blood marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  53. Blood biomarkers: activated partial thromboplastin time

    Blood marker measured in seconds (sec).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  54. Blood biomarkers: activated partial thromboplastin time ratio

    Blood marker.

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  55. Blood biomarkers: derived fibrinogen

    Blood marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  56. Blood biomarkers: procalcitonin

    Inflammatory response markers measured in nanograms/milliliter (ng/ml).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  57. Blood biomarkers: glycated hemoblobin A1c

    Metabolic and lipidic response marker measured in percentage (%).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  58. Blood biomarkers: estimated average glucose

    Metabolic and lipidic response marker measured in milligrams/deciliter (mg/dl).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  59. Blood biomarkers: carcinoembryonic antigen

    Tumor marker measured in nanograms per milliliter (ng/ml).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  60. Blood biomarkers: S-100

    Tumor markers measured in micrograms per liter (µg/L).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

Secondary outcomes

  1. EORTC_C30

    The patient self-reported outcomes comprised the EORTC_ C30 questionnaire. This survey assesses various dimensions of quality of life.

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  2. EORTC_OPT30

    The patient self-reported outcomes comprised also the complementary EORTC_ OPT30 module specifically designed for patients with eye cancer. This survey assesses various dimensions of quality of life, and the OPT30 module has a particular focus on evaluating visual functioning limitations.

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  3. HADS questionnaire

    The Hospital Anxiety and Depression Scale (HADS) will be used to measure symptoms of anxiety (HADS Anxiety) and depression (HADS Depression).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  4. Physical activity levels

    The patients will be also asked about their levels of physical activity prior to hospitalization (minutes/week during the last month).

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  5. TUG test

    To evaluate agility/coordination, the timed-up-and-go-test (TUG) will be used to, which consists of rising from a chair on command, walking a distance of 3 m, turning around, and walking back to the chair as fast as possible.

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

  6. 30s StS Test

    To assess muscle strength of lower limbs (endurance strength), the patient will be performed the 30-s sit-to-stand test (30 s StS), which is to stand up and sit down as many times as possible in 30 s.

    Time frame: At baseline, during hospital discharge day (5-7 days after baseline measure) and one month after hospital discharge.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
May 14, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970236
Responsible party
Joaquín Calatayud Villalba (Professor, University of Valencia) — Principal investigator
First posted
May 14, 2025
Start date
Feb 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion